Search filters

Oviva募集了2100万美元用于在欧洲推广数字化糖尿病治疗

Oviva筹集了2100万美元用于在欧洲推广数字化糖尿病治疗

该轮融资由瑞士医疗技术投资商MTIP牵头,Earlybird作为新投资者加入。 现有投资者AlbionVC,F-Prime Capital,Eight Roads Ventures和Partech跟投。 Oviva提供了一种基于循证的数字解决方案,以阻止2型糖尿病和肥胖相关疾病的发展并逆转。 患者通过手机获得量身定制的营养建议和个性化指导。 菲谢尔在本轮融资中为新投资者提供了法律建议。

VI...

Anaveon完成3500万瑞士法郎的A轮融资

免疫肿瘤生物技术公司Anaveon已成功完成了由英国生命科学基金Syncona牵头,诺华风险基金跟投的A轮融资。基于BaselArea.swiss的医疗保健加速器BaseLaunch提供的资金,该公司成立于2017年12月,2018年还从苏黎世大学生命科学基金筹集了额外的种子资金。Anaveon正在开发一种选择性白介素2受体(IL-2受体)激动剂,以增强患者的免疫系统对肿瘤的反应能力。天然存在的IL-2受体刺激一种称为T细胞的免疫细胞攻击肿瘤。...

Oculis获得新型II期抗TNFα抗体片段的授权

Oculis SA是在洛桑开发下一代局部眼科治疗药物的临床阶段生物制药公司,已签署一项协议,获得诺华公司授权许可的新型局部抗TNFα局部抗体。 该化合物名为LME 636,将重命名为OCS-02,该化合物基于专为局部递送而设计的专有单链抗体片段技术。

为Oculis提供咨询服务的VISCHER团队由Christian Wyss,Vincent Reardon,Vera Keller(均为公司法)和Adrian Briner(税务)组成。

Biovotion extends Series A Financing Round

VISCHER assists Harmony Medical Inc. as investor in the second closing of the ongoing CHF 10 m Series A financing round of Biovotion Ltd., Zürich. Biovotion Ltd is a leading wearable physiology monitoring company and provides...

Celgene acquires EngMab

Celgene (NASDAQ: CELG) has bought Swiss biotech EngMab for USD 600 million. EngMab's focus is on T-cell bispecific antibodies (TCBs). TCBs bind simultaneously to a target on a tumor cell and to the T-cell receptor complex, leading...

Decision of the Swiss Federal Administrative Court (Bundesverwaltungsgericht) Concerning the Rates of University Hospitals

The Swiss Federal Administrative Court (Bundesverwaltungsgericht) decided on important issues concerning the calculation of payment rates of university hospitals. VISCHER (Andreas Albrecht and Michael Waldner) represented the...

Sale and lease-back of kneipp-hof's operating real estate

Credit Suisse Real Estate Fund LivingPlus (CS REF LivingPlus) acquires all operating real estate from kneipp-hof Dussnang which leases the operating real estate back. The VISCHER Team, led by Benedict F. Christ (partner...

Vamed acquires kneipp-hof Dussnang AG

The international health care Provider VAMED (part of the German Fresenius group) extends its Swiss activities and acquires 100 percent of kneipp-hof Dussnang AG. This allows the seller, Kloster Heiligkreuz of Cham, to implement a...

Sonetik closes financing to fund further growth in the US

VISCHER advises Sonetik in a financing to fund further growth in the US. The participants in this Series A2 financing include existing investors, BB Biotech Ventures, and new investors joining the consortium, Aeris Capital. The...

You are currently offline. Some pages or content may fail to load.